10x Genomics, Inc. (TXG)
Pre-market:
| Previous close | 34.55 |
| Open | 34.67 |
| Bid | 32.76 x 200 |
| Ask | 32.86 x 100 |
| Day's range | 32.68 - 34.67 |
| 52-week range | 32.68 - 63.57 |
| Volume | |
| Avg. volume | 1,351,816 |
| Market cap | 3.916B |
| Beta (5Y monthly) | 1.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.18 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 57.07 |
PR Newswire10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible fro
PR Newswire10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.
- PR Newswire
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.
